Your Health, We Care
Another Name吉非替尼片、易瑞沙、伊瑞可、Gefitinib、Iressa
IndicationsIt is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have been confirmed to harbor EGFR exon 19 deletions or exon 21 (L858R) substitution mu
Reg No.09 L 1215/24
Inspection NO.2462-24
Gefitinib tablets produced by Lucius Pharmaceuticals achieve a good balance between efficacy and cost, providing a reliable treatment option for specific patients with EGFR-mutant non-small cell lung cancer.
The following is a summary of key information about Gefitinib tablets:
The main active ingredient is gefitinib, which belongs to a class of tyrosine kinase inhibitors.
It is indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) who have been confirmed by testing to have EGFR exon 19 deletions or exon 21 L858R mutations.
The recommended dose is 250 mg orally once daily, which can be taken with food or on an empty stomach.
It is contraindicated in pregnant women, and lactating women should discontinue breastfeeding.
Patients with liver impairment need close monitoring for adverse reactions.
No dosage adjustment is required for elderly patients.
In case of drug overdose, treatment should be discontinued and symptomatic and supportive care should be given. There is no specific antidote.
The medicine should be stored at room temperature between 20°C and 25°C, and protected from moisture.
The oral bioavailability of this drug is approximately 60%. It is mainly metabolized by the CYP3A4 enzyme, with a half-life of about 48 hours, and most of it is excreted through feces.
FDA，2021.05
